July 2004, Volume 34 Number 7 , p 26 - 27
© 2004 Lippincott Williams & Wilkins, Inc. Volume 34(7) July 2004 p 26–27 Inhaled antirejection drug shows promise [DRUG NEWS: LUNG TRANSPLANTS]
Lung transplant recipients who inhale an antirejection drug may increase their chances of survival fourfold, according to a new study. Patients undergoing this new, organ-specific approach to antirejection therapy inhale an experimental version of cyclosporine. Delivered directly to the lungs, the drug appears to stop immune cells from attacking vulnerable transplanted tissue.
In a study of 56 new lung recipients, half received the inhaled form of cyclosporine and half received a placebo inhalant. All patients used their inhalant 3 days a week for 2 years following their transplant. Patients in both groups also received standard antirejection therapy.
Researchers followed patients for 2 to 5 years after their transplant. ...